Oxford Pharmascience Group Plc | Medicines made better

 

Latest News

2015

04 December Grant of Share Options
01 December Holding(s) in Company
05 November Successful Completion of Proof-of-Concept for OXPzero™ Ibuprofen
22 September Interim results for the six months to 30 June 2015
16 September Notice of Results
12 August Preliminary Pharmacokinetic Data and
Initiation of Pilot Clinical Study
to Demonstrate Improved GI Profile for OXPzero™ Ibuprofen
31 July Encouraging Results from Pilot Clinical Study of OXPzero™ Naproxen (OXP005)
16 July Initiation of Pilot Clinical Study for Reduced Gastro-Intestinal Irritation Ibuprofen
16 July Initiation of Pilot Clinical Study for Reduced Gastro-Intestinal Irritation Ibuprofen
06 July Holding(s) in Company
30 June Holding(s) in Company
30 June Holding(s) in Company
30 June Holding(s) in Company
30 June Holding(s) in Company
30 June Holding(s) in Company
30 June Holding(s) in Company
24 June Result of AGM & General Meeting
09 June Posting of Circular and Notice of General Meeting
03 June Grant of Share Options
02 June Proposed £20 million Placing and Notice of General Meeting
18 May Initiation of Pilot Clinical Study for Reduced Gastro-Intestinal Irritation Naproxen
15 May Chewable Form of OXPzero™ Ibuprofen progressing to Proof-of-Concept Clinical Trial
13 May Pharmacokinetic (PK) Study Results for OXPzero™ Naproxen vs. Naprosyn®
15 April Holding(s) in Company
27 March Successful Pilot Clinical Study of Immediate Release OXPzero™ Naproxen
09 March Grant of Share Options
05 March Initiation of Comparative Pharmacokinetic (PK) Study of OXPzero™ Naproxen
05 March Results for the Year Ended 31 December 2014 and Notice of AGM
30 January Update on NSAIDs Programme & Year End Financial Review
20 January Naproxen Progresses into Proof of Concept Trials
08 January Successful optimisation of OXPZero™ Ibuprofen (OXP001) and progression to pilot clinical study